Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News CoLucid Pharmaceuticals CLCD

Healthcare Biotechnology
"CoLucid Pharmaceuticals Inc is a Phase 3 clinical-stage biopharmaceutical company that is developing a proprietary small molecule for the acute treatment of migraine headaches."
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CLCD)

Lilly Completes Acquisition of CoLucid Pharmaceuticals

PR Newswire March 1, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders

Business Wire February 2, 2017

Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm

Business Wire January 31, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD

PR Newswire January 31, 2017

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

Business Wire January 30, 2017

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD

Business Wire January 27, 2017

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

Business Wire January 23, 2017

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of CoLucid Pharmaceuticals, Inc. -CLCD

PR Newswire January 20, 2017

COLUCID SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of CoLucid Pharmaceuticals, Inc. (CLCD) Over the Proposed Sale of the Company to Eli Lilly and Company

PR Newswire January 20, 2017
View More News ››

Opinion & Analysis (NDAQ:CLCD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CLCD)

Be the first to post on this bullboard.

Masivo Silver Corp.

Masivo Silver Corp.

Masivo Silver Corp. is a Canada-based junior silver and gold mining exploration company. The Company is in the business of ...
View More »